BMJ  2007;335:651 (29 September), doi:10.1136/bmj.39289.649410.55 (published 11 September 2007)

Research

Cancer risk among users of oral contraceptives: cohort data from the Royal College of General Practitioner's oral contraception study

¹ Department of General Practice and Primary Care, University of Aberdeen, Aberdeen AB25 2AY , ² Centre for Rural Health, Beechwood Business Park, Inverness, ³ College of Life Sciences and Medicine, University of Aberdeen, Aberdeen

Objective To examine the absolute risks or benefits on cancer associated with oral contraception, using incident data.

Design Inception cohort study.

Setting Royal College of General Practitioners' oral contraception study.

Participants Directly standardised data from the Royal College of General Practitioners' oral contraception study.

Main outcome measures Adjusted relative risks between never and ever users of oral contraceptives for different types of cancer, main gynaecological cancers combined, and any cancer. Standardisation variables were age, smoking, parity, social class, and (for the general practitioner observation dataset) hormone replacement therapy. Subgroup analyses examined whether the relative risks changed with user characteristics, duration of oral contraception usage, and time since last use of oral contraception.

Results The main dataset contained about 339 000 woman years of observation for never users and 744 000 woman years for ever users. Compared with never users ever users had statistically significant lower rates of cancers of the large bowel or rectum, uterine body, and ovaries, tumours of unknown site, and other malignancies; main gynaecological cancers combined; and any cancer. The relative risk for any cancer in the smaller general practitioner observation dataset was not significantly reduced. Statistically significant trends of increasing risk of cervical and central nervous system or pituitary cancer, and decreasing risk of uterine body and ovarian malignancies, were seen with increasing duration of oral contraceptive use. Reduced relative risk estimates were observed for ovarian and uterine body cancer many years after stopping oral contraception, although some were not statistically significant. The estimated absolute rate reduction of any cancer among ever users was 45 or 10 per 100 000 woman years, depending on whether the main or general practitioner observation dataset was used.

Conclusion In this UK cohort, oral contraception was not associated with an overall increased risk of cancer; indeed it may even produce a net public health gain. The balance of cancer risks and benefits, however, may vary internationally, depending on patterns of oral contraception usage and the incidence of different cancers.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Relevant Articles

Study shows greater cancer risk

Joel Brind
BMJ 2008 336: 59-60. [Extract] [Full Text] [PDF]

Risk of cancer and the oral contraceptive pill

Olav Meirik and Timothy M M Farley
BMJ 2007 335: 621-622. [Extract] [Full Text] [PDF]

Long term effects of hysterectomy on mortality: nested cohort study

Lisa Iversen, Philip C Hannaford, Alison M Elliott, and Amanda J Lee
BMJ 2005 330: 1482. [Abstract] [Full Text] [PDF]

Mortality associated with oral contraceptive use: 25 year follow up of cohort of 46 000 women from Royal College of General Practitioners' oral contraception study

Valerie Beral, Carol Hermon, Clifford Kay, Philip Hannaford, Sarah Darby, and Gillian Reeves
BMJ 1999 318: 96-100. [Abstract] [Full Text] [PDF]

This article has been cited by other articles:

• Simon, C. (2008). The combined contraceptive. InnovAiT 1: 496-507 [Abstract] [Full text]  
• Kaunitz, A. M. (2008). Hormonal Contraception in Women of Older Reproductive Age. NEJM 358: 1262-1270 [Full text]  
• Brind, J. (2008). Study shows greater cancer risk. BMJ 336: 59-60 [Full text]  
• (2007). The Pill's Cancer Protection Confirmed. JWatch Women's Health 2007: 1-1 [Full text]  
• Meirik, O., Farley, T. M M (2007). Risk of cancer and the oral contraceptive pill. BMJ 335: 621-622 [Full text]  

Rapid Responses:

Read all Rapid Responses

Cancer risk and oral contraception use

Ana M. Ocana
bmj.com, 13 Sep 2007 [Full text]

Flawed RCGP Pill study underestimates cancer risks from use of progestogens and oestrogens.

Ellen C Grant
bmj.com, 16 Sep 2007 [Full text]

Validity of findings and interpretation of core results of the Royal College of General Practitioners` oral contraception study are questionable

Martina Dören, et al.
bmj.com, 14 Sep 2007 [Full text]

General Practitioner’s oral contraceptive study reveals greater; not lesser cancer risks

Joel Brind
bmj.com, 14 Dec 2007 [Full text]

Author's reponse

Philip C Hannaford, et al.
bmj.com, 21 Dec 2007 [Full text]

Re: Flawed RCGP Pill study underestimates cancer risks from use of progestogens and oestrogens.

Ellen C Grant
bmj.com, 22 Jan 2008 [Full text]

Re: Re: Flawed RCGP Pill study underestimates cancer risks from use of progestogens and oestrogens.

suzanne l adams
bmj.com, 6 Mar 2008 [Full text]